hta_ knee intro.qxp - Ministero della Salute

Table 7.6: Data from the Australian Orthopaedic Association National Joint Replacement Register
(AOAJRR) showing revision rates at 3 and 5 years by variables of the receiving population. This
table refers to uncemented fixation only.
Knee system (uncemented) Total obs.
Female/Male
[%]
Mean age
(range)
OA [%]
3 years
(95% CI)
5 years
(95% CI)
NEXGEN (ZIMMER) 5,874 53/47 69 (-) 97.3 2.0 (1.6; 2.4) 2.1 (1.7; 2.6)
SCORPIO (STRYKER) 3,351 56/46 69 (-) 97.9 3.1 (2.5; 3.9) 4.1 (3.3; 5.2)
DURACON (BIOMET) 2,948 52/48 69 (-) 97.2 2.7 (2.1; 3.4) 3.4 (2.7; 4.4)
ACTIVE KNEE (ASDM) 2,477 46/54 65 (-) 98.4 3.2 (2.5; 4.1) 4.1 (3.2; 5.3)
LCS (DEPUY) 2,309 55/45 68 (-) 97.3 3.3 (2.6; 4.1) 4.1 (3.3; 5.0)
RBK SYSTEM (G.M.T.) 1,971 54/46 68 (-) 98.7 2.6 (1.9; 3.6) 3.0 (2.1; 4.1)
NATURAL KNEE (ZIMMER) 1,685 51/49 68 (-) 98.2 2.3 (1.7; 3.2) 3.4 (2.6; 4.6)
PROFIX (SMITH & NEPHEW) 921 51/49 69 (-) 96.4 2.9 (1.9; 4.4) 3.6 (2.3; 5.5)
TRIATHLON (STRYKER) 752 44/56 67 (-) 98.7 - (-; -) - (-; -)
ADVANTIM (WRIGHT) 583 60/40 67 (-) 97.6 1.6 (0.7; 3.3) 1.6 (0.7; 3.3)
MAXIM (BIOMET) 576 55/45 69 (-) 97.4 3.2 (2.0; 5.0) 3.4 (2.2; 5.3)
NATURAL KNEE II (ZIMMER) 399 44/56 68 (-) 98.2 - (-; -) - (-; -)
ROTAGLIDE+ (CORIN) 347 49/51 68 (-) 97.7 3.2 (1.7; 6.0) 4.1 (2.3; 7.3)
ADVANCE (WRIGHT) 292 57/43 70 (-) 98.3 3.7 (2.0; 6.7) 4.8 (2.7; 8.3)
ROCC (BIOMET) 218 54/46 69 (-) 98.2 - (-; -) - (-; -)
NEXGEN LPS (ZIMMER) 193 53/47 67 (-) 97.4 - (-; -) - (-; -)
COLUMBUS (AESCULAP) 133 46/54 69 (-) 100 - (-; -) - (-; -)
GENESIS II (SMITH & NEPHEW) 111 49/61 64 (-) 98.2 - (-; -) - (-; -)
BUECHEL-PAPPAS (ENDOTEC) 69 45/55 69 (-) 97.1 - (-; -) - (-; -)
PROFIX OXINIUM (SMITH & NEPHEW) 53 58/42 63 (-) 96.2 - (-; -) - (-; -)
INTERAX (STRYKER) 51 43/57 72 (-) 92.2 2.0 (0.3; 13.6) 8.5 (3.3; 21.1)
Key: obs. = observations; CI = confidence interval; ASDM = Advanced Surgical Design & Manufacture;
G.M.T. = Global Manufacturing Technology; OA = osteoarthritis.
Note: Missing revision rates were marked with “- (-; -)”. This means that estimates at follow-up can not be calculated
yet (e.g. the number of observations was too low for survival analysis or the follow-up did not reach
3 years).
41